500k at 10.35p not huge but better than the selling . Let's wait and see |
bones69827 Mar '25 - 14:35 - 28221 of 28227
..... something has been leaked but ....
--------------------------------------
Bones,
Look at the very modest volume of shares traded today - who has the information leaked to? The chaps at the soup kitchen?
This is just retail trading and of no significance either way. |
He’s holding APTA
Showing signs of another placing
Talk about calling pot kettle black |
I remember when Bones was scaring people to sell into 8p bid. Then it shot up to 17p.He has multiple IDs, you should know that of course |
GDR placing bones announced !!!
1.5 pence |
CPAI show’s optimism !!
Pwhite tried convincing me i was wrong
So i bought more odviously
.6 now nearly 4 bagged
Point being
Money stuck in this 20 year fantasy, has not just lost you money on equity price
But on far far better opportunities |
washingmachine, oh how I wish I could match your joy, goodwill and optimism. |
More like the rise before a placing |
Interesting move today looks like the seller might have cleared finally just in time for a new tax year . Been a lot of that around aim shares recently . Either that or something has been leaked but I'll go with the first without evidence |
My aching brain hopes you are right! |
I reckon 30-50p will be hit in the coming quarter.
Astrazeneca deal seems extremely likely going by the information presented in the recent RNS. |
No news, good news!-:) |
make their option worthless |
Following the issue of these options, the Company will have outstanding options over a total of up to 51,369,480 Ordinary Shares, representing approximately 13.7% of its issued and to be issued share capital, which is within the Remuneration Policy approved limit of up to 16%.
The exercise price for the Staff Share Options is 10.00 pence per Ordinary Share, being 2.6% above the Company's closing mid-market share price of 9.75 pence per Ordinary Share on 20 March 2025, being the latest practicable date prior to this announcement. The Staff Share Options are subject to certain service and/or performance conditions over a three-year period. |
The pdfile Robspaz is biggest loser on advfn.
bankrupt pdfile |
Krypton even if correct you have answered your own question
Astra
Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025."
Then comes the review, and 6-12months of talking if you are thinking a swift deal.
It took years to get first deal with them.
As Yas points out a deal anytime soon is highly unlikely, Yas is waiting for either AGL hype or some investor generated hype and buying to exit.
Drifting along here will sting somewhat if it’s still at this level in the last week of a fund raise event, the share price would turn downwards as those offering support lower their offer.
It’s coming and it’s not too far away.
All about Astra as Yas says and the chances of anything soon are very slim. |
Bones on your point near news.
The company pushed BS forecasts to backers in the raise last time and filled investors of hope of large companies in talks and gave it a number.
At the AGM, 1 deal before YE and possibly another, which highlighted the earlier point of a very tall order highly unlikely to meet the target.
The one deal wasn’t even newsworthy, slipped in other news.
Eisai dead but still punters hold on whilst it’s headed for a an obvious fund raise, going to the market with the previous exaggerated claims now laid bare.
Large trades have now been apparent for a week or so, late reporting and the share price in recent time has slumped back.
Those large trades could simply be non existent stock forward sold to recoup by the suppliers in the pending raise.
As Yas has pointed out any good news and it’s get out time on a hoped for spike to avoid the inevitable discount raise.
It would take something way above normal news to be anything other than a chance to get out pre raise. |
 Good spot Bermudashorts - good to hear that the Bioview collaboration is generating worthwhile data.
If memory serves & I'm not mistaken, Bioview were adding some refinements to their equipment.
A recap on the original announcement & perhaps worth noting that they are also FDA cleared :
"BioView develops, manufactures and markets innovative automated cell imaging and analysis solutions and has received FDA product clearance for its fluorescent in situ hybridisation (FISH) application for HER2 analysis of FFPE breast tissue sections, hybridised with Abbott's PathVysion HER2 DNA probe kit (see hxxps://bioview.com/applications/pathology/breast/). ANGLE has already successfully integrated BioView's technology in its R&D and clinical laboratories for assay development and pharma services.
ANGLE and BioView will now begin the programme of developing a HER2 assay for the detection of HER2 protein via immunofluorescence (IF) and HER2/neu gene amplification by FISH, utilising Abbott's PathVysion HER2 DNA probe kit, in CTCs from breast cancer patients' blood samples harvested using ANGLE's FDA cleared Parsortix PC1 Clinical System and analysed using BioView's automated imaging and analysis technology." |
It's all helpful to momentum but I tend to Yasx's point that as it stands there's no value to Angle shareholders. |
The AACR Annual Meeting is being held in April in Chicago. It's a major international event with over 20,000 attendees. Abstracts were published tonight and great to see that Angle will be presenting a poster on 28th April:-
'Analytical validation of ANGLE's combined IF and FISH assay for assessment of HER2 in circulating tumor cells'
This is clearly a continuation of the collaboration with BioView and they appear to have developed a combined IF and FISH assay to assess HER2 status from a single CTC liquid biopsy. From the abstract:-
'Analytical specificity and sensitivity of all IF markers were >96%. Analytical specificity and sensitivity of the FISH assay were 100%. The assay was shown to be repeatable and reproducible.
Conclusion: This study demonstrated that ANGLE’s combined IF and FISH assay is a robust method for determination of HER2 protein expression and concomitant interrogation of HER2 gene amplification on the cancer cells. This workflow will be utilized to analyze CTCs isolated from a cohort of ~100 metastatic BC patients to evaluate its clinical feasibility and validity and these results will be reported at the AACR annual meeting.'
Clearly a huge amount of work is going on at Angle's labs and looking forward to hearing the results of that 100 patient study when they're presented in April. Good stuff. |
Wow impressive ZoleTrader. Thank you and im sure all genuine holders appreciate your work. No smoke without fire.. suprised at market reaction after last update. Market will hopefully recognise the significance soon... Buy |
ST,
Your lengthy piece referencing various AZ trials is noted
How much has Angle made from those? Any idea? No, thought not.
Allow me to confirm the figure to you: zero.
That ST, is all that matters. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
